May is Brain Tumor Awareness Month
Melanoma cells are one of the most common cancers that can migrate to the brain, creating a new challenge for…
04/12/2024
May is Brain Tumor Awareness Month
Melanoma cells are one of the most common cancers that can migrate to the brain, creating a new challenge for…
04/11/2024
President’s Letter | April 2024
From the Desk of Samantha Guild Happy Spring! Spring is a season of things new and renewed, and this newsletter…
|
04/11/2024
Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk
By Mara Klecker On April 20th, melanoma survivors, their families, and supporters will gather in Dallas for the annual AIM…
|
04/11/2024
Interview with Allison Betof Warner, MD, PhD: TIL Therapy
The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…
|
04/11/2024
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Note: We are rerunning an update on this TIL therapy article that originally ran…
|
|
04/05/2024
Secure Your Legacy With a Click
Ways to Give: Estate Gifts First Article in a Series Here at AIM at Melanoma, we are fortunate to be…
|
03/20/2024
Elizabeth’s Battle Against Melanoma: How Clinical Trials Changed Her Life
By Mara Klecker Elizabeth Rounseville hardly knew what melanoma was when she was diagnosed in 2018 after going to see…
|
03/15/2024
The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
|
|
03/13/2024
Exploring the Healing Power of Animals
Ever wondered how animals can make a huge difference in people’s lives? In this podcast, we delve into the fascinating…
|
03/07/2024
EXCLUSIVE WEBINAR: The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA-approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of…
|
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026